102 filings
Page 4 of 6
8-K
13m e84eeuvcacg2xc
10 Apr 18
Kadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD025 in Chronic Graft-Versus-Host Disease
12:00am
8-K
mmfr4ff401
9 Apr 18
Departure of Directors or Certain Officers
12:00am
8-K
yfpyoa5qvtoazl
6 Mar 18
Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2017 Financial Results
12:00am
8-K
0q0gd 6fa5
23 Feb 18
Kadmon Announces Updated Positive Results from Phase 2 Study of KD025 in cGVHD
12:00am
8-K
fm5cx0d wp53vgusjfd
12 Feb 18
Kadmon Announces Positive Topline Results from Phase 2 Study of KD025
12:00am
8-K
kuy8d0a5
26 Dec 17
Other Events
12:00am
8-K
yjlhn9f2x ji
11 Dec 17
Regulation FD Disclosure
12:00am
8-K
sykq81u3
11 Dec 17
Kadmon Presents Updated Positive Phase 2 Data on KD025 in cGVHD at ASH Annual Meeting
12:00am
8-K
gxzbtzj3k41m5ag2
13 Nov 17
Other Events
12:00am
8-K
aunb16q3
9 Nov 17
Kadmon Provides Business Update and Reports Third Quarter 2017 Financial Results
12:00am
8-K
tooyun 68z35lhax
6 Oct 17
Departure of Directors or Certain Officers
12:00am
8-K
h60hu
28 Sep 17
Kadmon Announces Pricing of Public Offerings of Common Stock and Warrants
12:00am
8-K
9x08u epxi
25 Sep 17
Kadmon Announces Proposed Public Offering of Common Stock and Warrants
12:00am
8-K
5zyyltli
14 Aug 17
Entry into a Material Definitive Agreement
12:00am
8-K
sw3h95l
3 Aug 17
Kadmon Provides Business Update and Reports Second Quarter 2017 Financial Results
12:00am
8-K
h22u06lt9
25 Jul 17
Kadmon Announces Supplemental Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
12:00am
8-K
f6p7anfcax55ozpz
11 Jul 17
Kadmon Announces Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
12:00am
8-K
0inx k2do
29 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
s24qrhs2rz vgsw13
23 Jun 17
Kadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease (cGVHD) at R&D Day
12:00am
8-K
hfsbjf8n
14 Jun 17
Departure of Directors or Certain Officers
12:00am